Breaking News, Collaborations & Alliances

Open Monoclonal Technology Forms Alliance With Five Prime

Becomes OMT’s 16th corporate partner globally with such multi-platform OmniAb access

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Open Monoclonal Technology Inc. (OMT) has licensed its proprietary OmniRat, OmniMouse and OmniFlic human antibody generation platforms to Five Prime Therapeutics Inc., making it OMT’s 16th corporate partner globally with such multi-platform access. “Five Prime’s large collection of medically relevant extracellular proteins combined with its sophisticated screening technology is particularly well suited for the identification of therapeutic human antibody targets,” said Roland Buelow, OM...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters